文献速递脑血管病外科神经重症

REACT:评估克拉生坦预防动脉瘤性蛛网膜下腔出血后迟发性脑缺血所致临床恶化的疗效与安全性的随机试验

REACT: a randomized trial to assess the efficacy and safety of clazosentan for preventing clinical deterioration due to delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage.
PubMed 文献 · J Neurosurg · 2024-08-09

REACT为前瞻性、多中心、随机、双盲3期研究,纳入409例经夹闭或栓塞处理、入院CT见厚而弥漫血凝块的aSAH患者,按1:1随机接受克拉生坦15 mg/h静脉给药或安慰剂,最长14天。结果显示克拉生坦组迟发性脑缺血所致临床恶化发生率为15.8%(32/202),安慰剂组为17.2%(35/204),差异无统计学意义。

要点

  • 克拉生坦组迟发性脑缺血所致临床恶化15.8%(32/202) vs 安慰剂组17.2%(35/204),差异无统计学意义。
  • 克拉生坦组挽救治疗需求10.4%(21/202) vs 安慰剂组18.1%(37/204),相对风险降低42.6%(95%CI 5.4%-65.2%)。
  • 第12周不良GOSE和mRS评分风险克拉生坦组24.8%(50/202) vs 安慰剂组20.1%(41/204),相对风险增加25.4%,未达统计学显著。

核心结论

  • 克拉生坦以15 mg/h给药最长14天对迟发性脑缺血所致临床恶化的发生无显著影响。

研究设计与样本

  • 前瞻性、多中心、随机、双盲3期研究;2019年2月至2022年5月在74个国际中心随机409例,3例未开始研究治疗而未纳入分析集。
  • 纳入经手术夹闭或血管内栓塞处理的aSAH患者,入院CT见厚而弥漫的血凝块。
  • 按1:1随机接受克拉生坦15 mg/h静脉给药或安慰剂,于aSAH后96小时内开始、最长14天,并联合包括口服或静脉尼莫地平在内的标准治疗。

主要发现

  • 迟发性脑缺血所致临床恶化:克拉生坦组15.8%(32/202) vs 安慰剂组17.2%(35/204),相对风险降低7.2%(95%CI -42.6%至39.6%,p=0.734),差异无统计学意义。
  • 临床相关脑梗死:克拉生坦组7.4%(15/202) vs 安慰剂组11.3%(23/204),相对风险降低34.1%(95%CI -21.3%至64.2%,p=0.177),未达统计学显著。
  • 挽救治疗需求:克拉生坦组10.4%(21/202) vs 安慰剂组18.1%(37/204),相对风险降低42.6%(95%CI 5.4%-65.2%)。
  • aSAH后第12周不良GOSE和mRS评分风险:克拉生坦组24.8%(50/202) vs 安慰剂组20.1%(41/204),相对风险增加25.4%(95%CI -10.7%至76.0%,p=0.198),未达统计学显著。
  • 治疗中出现的不良事件与既往报告相似。

关键数值与推荐

  • 主要疗效终点为开始研究药物后14天内迟发性脑缺血所致临床恶化的发生。
  • 主要次要终点为开始研究药物后第16天临床相关脑梗死的发生。
  • 其他次要终点包括aSAH后第12周mRS和GOSE评估的临床结局;影像学和临床终点由中心裁定。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Ischemic complications account for significant patient morbidity following aneurysmal subarachnoid hemorrhage (aSAH). The Prevention and Treatment of Vasospasm with Clazosentan (REACT) study was designed to assess the safety and efficacy of clazosentan, an endothelin receptor antagonist, in preventing clinical deterioration due to delayed cerebral ischemia (DCI) in patients with aSAH. METHODS: REACT was a prospective, multicenter, randomized, double-blind, phase 3 study. Eligible patients had aSAH secured by surgical clipping or endovascular coiling, and had presented with thick and diffuse clot on admission CT scan. Patients were randomized (1:1 ratio) to 15 mg/hour intravenous clazosentan or placebo within 96 hours of the aSAH for up to 14 days, in addition to standard of care treatment including oral or intravenous nimodipine. The primary efficacy endpoint was the occurrence of clinical deterioration due to DCI up to 14 days after initiation of the study drug. The main secondary endpoint was the occurrence of clinically relevant cerebral infarction at day 16 after study drug initiation. Other secondary endpoints included clinical outcome assessed on the modified Rankin Scale (mRS) and the Glasgow Outcome Scale-Extended (GOSE) at week 12 post-aSAH. Imaging and clinical endpoints were centrally adjudicated. RESULTS: A total of 409 patients were randomized between February 2019 and May 2022 across 74 international sites. Three patients did not start study treatment and were not included in the analysis set. The occurrence of clinical deterioration due to DCI was 15.8% (32/202 patients) in the clazosentan group and 17.2% (35/204 patients) in the placebo group, and the difference was not statistically significant (relative risk reduction [RRR] 7.2%, 95% CI -42.6% to 39.6%, p = 0.734). A nonsignificant RRR of 34.1% (95% CI -21.3% to 64.2%, p = 0.177) was observed in clinically relevant cerebral infarcts treated with clazosentan (7.4%, 15/202) versus placebo (11.3%, 23/204). Rescue therapy was less frequently needed for patients treated with clazosentan compared to placebo (10.4%, 21/202 vs 18.1%, 37/204; RRR 42.6%, 95% CI 5.4%-65.2%). A nonsignificant relative risk increase of 25.4% (95% CI -10.7% to 76.0%, p = 0.198) was reported in the risk of poor GOSE and mRS scores with clazosentan (24.8%, 50/202) versus placebo (20.1%, 41/204) at week 12 post-aSAH. Treatment-emergent adverse events were similar to those reported previously. CONCLUSIONS: Clazosentan administered for up to 14 days at 15 mg/hour had no significant effect on the occurrence of clinical deterioration due to DCI. Clinical trial registration no.: NCT03585270 (ClinicalTrials.gov) EU clinical trial registration no.: 2018-000241-39 (clinicaltrialsregister.eu).

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Mayer SA, Bruder N, Citerio G, et al. REACT: a randomized trial to assess the efficacy and safety of clazosentan for preventing clinical deterioration due to delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. J Neurosurg. 2024. PMID: 39126720. doi:10.3171/2024.4.JNS232191

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。